AB Science annonce aujourd'hui la publication des résultats de son étude positive du masitinib dans l'asthme sévère non contrôlé par les corticostéroïdes oraux dans la revue évaluée par des pairs Journal of Asthma and Allergy
June 07, 2022 11:45 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION DANS LA REVUE JOURNAL OF ASTHMA AND ALLERGY DES RÉSULTATS POSITIFS DE L'ETUDE DE PHASE 3 DU MASITINIB CHEZ LES PATIENTS SOUFFRANT D'ASTHME...
Global Allergy Diagnostics Market Report 2022: Market to Reach US$5.7 Billion by 2026 - Increasing Prevalence and Incidence of Allergic Disorders to Drive the Demand
June 07, 2022 05:48 ET
|
Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Allergy Diagnostics...
Global Allergen Blocker Market Report to 2027 - Featuring Trutek, Prestige Brands and Ecology Works Among Others
June 07, 2022 04:53 ET
|
Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergen Blocker Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
April 28, 2022 07:23 ET
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
February 08, 2022 08:30 ET
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
January 25, 2022 05:23 ET
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
December 21, 2021 09:39 ET
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Therapeutic Dog Food Market Size Worth $8,949.52 Million, Globally, by 2028 at 5.6% CAGR - Exclusive Report by The Insight Partners
December 16, 2021 05:41 ET
|
The Insight Partners
New York, Dec. 16, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Therapeutic Dog Food Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Dry Food,...